AI Article Synopsis
- Haemorrhagic cystitis (HC) is marked by ongoing blood in urine and urinary issues after chemotherapy or radiotherapy, with unclear causes likely linked to drug toxicity or radiation damage.
- Current treatment options are not standardized, but methods like fulguration and hyperbaric oxygen therapy have shown short-term benefits in studies.
- New therapies, such as liposomal tacrolimus, are being explored as potential future treatments, with the review covering the incidence, causes, and management strategies for HC.
Article Abstract
Haemorrhagic cystitis (HC) is characterised by persistent haematuria and lower urinary tract symptoms following radiotherapy or chemotherapy. Its pathogenesis is poorly understood but thought to be related to acrolein toxicity following chemotherapy or fibrosis/vascular remodelling after radiotherapy. There is no standard of care for patients with HC, although existing strategies including fulguration, hyperbaric oxygen therapy, botulinum toxin A, and other intravesical therapies have demonstrated short-term efficacy in cohort studies. Novel agents including liposomal tacrolimus are promising targets for further research. This review summarises the incidence and pathogenesis of HC as well as current evidence supporting its different management strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bju.16140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!